Ying Luo
Fondateur chez GNI GROUP LTD.
Fortune : 53 M $ au 31/05/2024
Profil
Ying Luo is the founder of Shanghai Genomics, Inc. (founded in 2001) and holds the title of Chairman.
They are also the founder of GNI Group Ltd.
(founded in 2005) and hold the titles of Executive President, CEO & Representative Director.
Additionally, Dr. Luo is the founder of Cullgen, Inc. (founded in 2018) and holds the titles of Chairman, President & Chief Executive Officer.
Dr. Luo's current job(s) include being the Chairman & Chief Executive Officer at GNI-EPS Pharmaceuticals, Inc. (since 2010), Chairman at Continent Pharmaceutical Inc. (since 2011), Chairman at Beijing Continent Pharmaceutical Co., Ltd.
(since 2011), Chairman & General Manager at Cullgen Shanghai, Inc. (since 2018), Chairman at Shanghai GEP Pharmaceuticals, Inc. (since 2017), Chairman at Gyre Therapeutics, Inc. (since 2023), and President & Director at GNI USA, Inc. (since 2015).
Dr. Luo's former job(s) include being the Chairman & Chief Executive Officer at GNI Hong Kong Ltd., Chairman at Catalyst Biosciences, Inc., Director at Berkeley Advanced Biomaterials, Inc., Director-Functional Genomics Division II at Chinese National Genome Center (from 2001 to 2011), and Adjunct Professor at Shanghai Jiao Tong University.
Dr. Luo's education history includes a doctorate degree from the University of Connecticut Health Center (conferred in 1991) and an undergraduate degree from Peking Union Medical College (conferred in 1986).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
3,32% | 19/03/2024 | 2 840 376 ( 3,32% ) | 32 M $ | 31/05/2024 |
GNI GROUP LTD.
2,90% | 31/12/2023 | 1 447 700 ( 2,90% ) | 20 M $ | 31/05/2024 |
Postes actifs de Ying Luo
| Sociétés | Poste | Début |
|---|---|---|
| GNI GROUP LTD. | Fondateur | 01/06/2005 |
Continent Pharmaceutical Inc.
 Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Président | 01/09/2011 |
Shanghai GEP Pharmaceuticals, Inc.
 Shanghai GEP Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shanghai GEP Pharmaceuticals, Inc. is a private company that manufactures pharmaceutical products. The company is based in Shanghai, China. | Président | 01/11/2017 |
| Cullgen Shanghai, Inc. | Président | 01/06/2018 |
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Président | 01/09/2011 |
Cullgen, Inc.
 Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | Directeur Général | 01/01/2018 |
Shanghai Genomics, Inc.
 Shanghai Genomics, Inc. Pharmaceuticals: MajorHealth Technology Part of GNI Group Ltd., Shanghai Genomics, Inc. engages in therapeutic pharmaceutical products development and production. The company is based in Shanghai, China. Shanghai Genomics was acquired by GNI Group Ltd. on June 20, 2005. The Chinese company was founded by Ying Luo, Jun Wu. | Fondateur | 01/05/2001 |
GNI USA, Inc.
 GNI USA, Inc. BiotechnologyHealth Technology GNI USA, Inc. engages in therapeutic pharmaceutical products development and production. The company was founded in 2001 and is headquartered in San Jose, CA. | President | 01/01/2015 |
| GNI-EPS Pharmaceuticals, inc. | Directeur Général | 01/11/2010 |
Anciens postes connus de Ying Luo
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░ ░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░ ░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Formation de Ying Luo
| University of Connecticut Health Center | Doctorate Degree |
| Peking Union Medical College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GNI GROUP LTD. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Shanghai Genomics, Inc.
Shanghai Genomics, Inc. Pharmaceuticals: MajorHealth Technology Part of GNI Group Ltd., Shanghai Genomics, Inc. engages in therapeutic pharmaceutical products development and production. The company is based in Shanghai, China. Shanghai Genomics was acquired by GNI Group Ltd. on June 20, 2005. The Chinese company was founded by Ying Luo, Jun Wu. | Health Technology |
Berkeley Advanced Biomaterials, Inc.
 Berkeley Advanced Biomaterials, Inc. Pharmaceuticals: MajorHealth Technology Berkeley Advanced Biomaterials, Inc. manufactures and distributes calcium-based products. Its products include HAP/TCP, nanocrystals, powder, granules and blocks. The company was incorporated by François Génin in October 1996 and is headquartered in Berkeley, CA. | Health Technology |
| Chinese National Genome Center | |
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
| GNI-EPS Pharmaceuticals, inc. | |
GNI Hong Kong Ltd.
 GNI Hong Kong Ltd. Miscellaneous Commercial ServicesCommercial Services GNI Hong Kong Ltd. engages in property management. The company was founded on July 31, 2013 and is headquartered in Hong Kong. | Commercial Services |
GNI USA, Inc.
GNI USA, Inc. BiotechnologyHealth Technology GNI USA, Inc. engages in therapeutic pharmaceutical products development and production. The company was founded in 2001 and is headquartered in San Jose, CA. | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
Cullgen, Inc.
Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | Health Technology |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
| Cullgen Shanghai, Inc. | |
Shanghai GEP Pharmaceuticals, Inc.
Shanghai GEP Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shanghai GEP Pharmaceuticals, Inc. is a private company that manufactures pharmaceutical products. The company is based in Shanghai, China. | Health Technology |
